| Literature DB >> 31461850 |
Paweł Kwiatkowski1, Agata Pruss2, Bartosz Wojciuk3, Barbara Dołęgowska2, Anna Wajs-Bonikowska4, Monika Sienkiewicz5, Monika Mężyńska6, Łukasz Łopusiewicz6.
Abstract
Because of the bacterial drug resistance development, it is reasonable to investigate chemical compounds capable of preventing the spread of resistance to mupirocin (MUP), commonly used in staphylococcal eradication. The objective of the study was to verify the influence of essential oil compounds (EOCs) on the antibacterial activity of MUP against mupirocin-susceptible (MupS) and induced low-level mupirocin-resistant (MupRL) methicillin-resistant Staphylococcus aureus (MRSA) strains. The following parameters were examined: MRSAMupS and MRSAMupRL susceptibility to EOCs (1,8-cineole, eugenol, carvacrol, linalool, (-)-menthone, linalyl acetate, and trans-anethole), the bacterial cell size distribution, and chemical composition by the use of Fourier Transform Infrared Spectroscopy (FTIR) and Raman spectroscopies. The MRSAMupS and MRSAMupRL strains were susceptible to all tested EOCs. 1,8-cineole and (-)-menthone showed synergistic activity against MRSAMupS in combination with mupirocin, whereas 1,8-cineole exhibited synergistic activity against MRSAMupRL as well. In-depth analysis showed that both MRSAMupS and MRSAMupRL displayed similar distributions of the bacterial cell size. The FTIR and Raman spectra of the MRSAMupS and MRSAMupRL strains showed differences in some regions. New bands in the MRSAMupRL Raman spectrum were observed. It was concluded that the use of 1,8-cineole in combination with mupirocin can increase the mupirocin activity against the MRSAMupS and MRSAMupRL strains.Entities:
Keywords: FTIR; MRSA; Raman spectroscopy; essential oil compounds; low-level mupirocin-resistant; mupirocin-susceptible; synergistic activity
Year: 2019 PMID: 31461850 PMCID: PMC6749447 DOI: 10.3390/molecules24173105
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Fractional inhibitory concentration (FIC) and FIC indices (FICI) of mupirocin-essential oil compound (EOC) pairs against mupirocin-susceptible (MRSAMupS) and induced low-level mupirocin-resistant (MRSAMupRL) strains.
| Strains | Mupirocin-EOCs | MICO | MICC | FIC | FICI | Type of Interaction |
|---|---|---|---|---|---|---|
| MRSAMupS | Mupirocin-1,8-cineole | |||||
| Mupirocin (mg/L) | 0.24 ± 0.00 | 0.06 ± 0.00 | 0.25 | 0.44 | synergy | |
| 1,8-cineole (mg/mL) | 307.00 ± 132.93 | 57.56 ± 0.00 | 0.19 | |||
| Mupirocin-eugenol | ||||||
| Mupirocin (mg/L) | 0.24 ± 0.00 | 0.24 ± 0.00 | 1.0 | 5.0 | antagonism | |
| Eugenol (mg/mL) | 2.08 ± 0.00 | 8.34 ± 0.00 | 4.0 | |||
| Mupirocin-carvacrol | ||||||
| Mupirocin (mg/L) | 0.24 ± 0.00 | 0.24 ± 0.00 | 1.0 | 5.0 | antagonism | |
| Carvacrol (mg/mL) | 0.95 ± 0.00 | 3.81 ± 0.00 | 4.0 | |||
| Mupirocin-linalool | ||||||
| Mupirocin (mg/L) | 0.24 ± 0.00 | 0.24 ± 0.00 | 1.0 | 1.5 | indifference | |
| Linalool (mg/mL) | 6.8 ± 1.0 | 3.4 ± 0.0 | 0.5 | |||
| Mupirocin-(-)-menthone | ||||||
| Mupirocin (mg/L) | 0.24 ± 0.00 | 0.06 ± 0.00 | 0.25 | 0.38 | synergy | |
| (-)-Menthone (mg/mL) | 27.91 ± 0.00 | 3.49 ± 0.00 | 0.13 | |||
| Mupirocin-linalyl acetate | ||||||
| Mupirocin (mg/L) | 0.24 ± 0.00 | 0.12 ± 0.00 | 0.5 | 1.5 | indifference | |
| Linalyl acetate (mg/mL) | 450.5 ± 0.0 | 450.5 ± 0.0 | 1.0 | |||
| Mupirocin- | ||||||
| Mupirocin (mg/L) | 0.24 ± 0.00 | 0.24 ± 0.00 | 1.0 | 2.0 | indifference | |
| 494.0 ± 0.0 | 494.0 ± 0.0 | 1.0 | ||||
| MRSAMupRL | Mupirocin-1,8-cineole | |||||
| Mupirocin (mg/L) | 31.25 ± 0.00 | 0.98 ± 0.00 | 0.03 | 0.28 | synergy | |
| 1,8-cineole (mg/mL) | 57.56 ± 0.00 | 14.39 ± 0.00 | 0.25 | |||
| Mupirocin-eugenol | ||||||
| Mupirocin (mg/L) | 31.25 ± 0.00 | 15.63 ± 0.00 | 0.5 | 1.0 | addition | |
| Eugenol (mg/mL) | 8.34 ± 0.00 | 4.17 ± 0.00 | 0.5 | |||
| Mupirocin-carvacrol | ||||||
| Mupirocin (mg/L) | 31.25 ± 0.00 | 15.63 ± 0.00 | 0.50 | 0.75 | addition | |
| Carvacrol (mg/mL) | 0.48 ± 0.00 | 0.12 ± 0.00 | 0.25 | |||
| Mupirocin-linalool | ||||||
| Mupirocin (mg/L) | 31.25 ± 0.00 | 62.5 ± 0.0 | 2.0 | 11.6 | antagonism | |
| Linalool (mg/mL) | 2.83 ± 0.98 | 27.19 ± 0.00 | 9.6 | |||
| Mupirocin-(-)-menthone | ||||||
| Mupirocin (mg/L) | 31.25 ± 0.00 | 62.5 ± 0.0 | 2.0 | 18.0 | antagonism | |
| (-)-Menthone (mg/mL) | 6.98 ± 0.00 | 111.63 ± 0.00 | 16.0 | |||
| Mupirocin-linalyl acetate | ||||||
| Mupirocin (mg/L) | 31.25 ± 0.00 | 31.25 ± 0.00 | 1.0 | 2.0 | indifference | |
| Linalyl acetate (mg/mL) | 450.5 ± 0.0 | 450.5 ± 0.0 | 1.0 | |||
| Mupirocin- | ||||||
| Mupirocin (mg/L) | 31.25 ± 0.00 | 7.81 ± 0.00 | 0.25 | 0.74 | addition | |
| 494.0 ± 0.0 | 247.0 ± 0.0 | 0.49 | ||||
Values are expressed as mean ± standard deviation. MICo, MIC of EOC or mupirocin; MICc, MIC of EOC/mupirocin combination. FIC index = FIC of EOC + FIC of mupirocin. FICI < 0.5, synergy; 0.5 ≤ FICI ≤ 1.0, addition; 1.1 < FICI ≤ 4.0, indifference; FICI > 4.0, antagonism. Using the known concentrations of EOCs, the final result was expressed in mg/mL.
Figure 1Comparison of the sizes of growing MRSAMupS and MRSAMupRL colonies on Columbia agar with 5% sheep blood (a), and cells using Mastersizer 2000 (b), and SEM (c).
Figure 2FTIR spectra of MRSAMupS and MRSAMupRL strains.
Figure 3Raman spectra of MRSAMupS and MRSAMupRL strains.